Durão V, Prata M M, Gonçalves L M
Lancet. 1977 Nov 12;2(8046):1005-7. doi: 10.1016/s0140-6736(77)92899-9.
The effect of indomethacin-induced inhibition of endogenous prostaglandin synthesis on the antihypertensive activity of pindolol (15 mg daily) and propranolol (80--160 mg daily) was studied in 7 hypertensive patients. In four test phases of 10 days each, patients received beta-blocker alone, placebo, beta-blocker plus indomethacin (100 mg daily), and beta-blocker alone. Mean supine diastolic blood-pressure rose from 82 +/- 2 mm Hg in the first beta-blocker phase to 98 +/- 3 mm Hg in the placebo phase, remained elevated (96 +/- 3 mm Hg) in the beta-blocker-plus-indomethacin phase, and fell to 83 +/- 3 mm Hg in the last beta-blocker phase. Diastolic blood-pressure values obtained in the beta-blocker-plus-indomethacin phase were not significantly different from those obtained in the placebo phase but were significantly different from the values measured in both beta-blocker phases (P less than 0-01). The changes in systolic blood-pressure and pulse-rate were not significant. These preliminary results suggest that the antihypertensive effect of these two beta-blockers in some hypertensive patients may be related to the endogenous prostaglandin system.
在7名高血压患者中研究了吲哚美辛诱导的内源性前列腺素合成抑制对吲哚洛尔(每日15毫克)和普萘洛尔(每日80 - 160毫克)降压活性的影响。在四个各为期10天的测试阶段,患者分别接受单独使用β受体阻滞剂、安慰剂、β受体阻滞剂加吲哚美辛(每日100毫克),然后再次单独使用β受体阻滞剂。平均仰卧舒张压从第一个β受体阻滞剂阶段的82±2毫米汞柱升至安慰剂阶段的98±3毫米汞柱,在β受体阻滞剂加吲哚美辛阶段保持升高(96±3毫米汞柱),并在最后一个β受体阻滞剂阶段降至83±3毫米汞柱。β受体阻滞剂加吲哚美辛阶段获得的舒张压值与安慰剂阶段获得的值无显著差异,但与两个β受体阻滞剂阶段测得的值有显著差异(P小于0.01)。收缩压和脉搏率的变化不显著。这些初步结果表明,这两种β受体阻滞剂在一些高血压患者中的降压作用可能与内源性前列腺素系统有关。